# A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

> **NCT03625141** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 80 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Atezolizumab
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT03625141
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2021-06-07
- **Final completion:** 2023-04-13
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03625141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03625141, "A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03625141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*